R Lam1, H Li2, M L Nock3. 1. Division of Neonatology, Department of Pediatrics, Oregon Health and Science University, Doernbecher Children's Hospital, Portland, OR, USA. 2. Center for Clinical Investigation, Case Western Reserve University, Cleveland, OH, USA. 3. Division of Neonatology, Department of Pediatrics, University Hospitals Case Medical Center Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
Abstract
OBJECTIVE: Targeted screening for glucose-6-phosphate dehydrogenase deficiency (G6PDdef) using fluorescent spot test (FST) is done in our newborn nursery (NN) and now in our NICU. Premature infants have higher G6PD levels than term infants. FST may result in under diagnosis of G6PDdef in preterms. We sought to determine if FST is appropriate for diagnosis of G6PDdef at<35 weeks and assess screening in NICU. STUDY DESIGN: Retrospective chart review of male, inborn infants<35 weeks in NICU from 2008 to 2011. Difference in G6PDdef incidence<5% between NN and NICU was acceptable for equivalence. RESULTS: Out of 679 subjects, 442 were screened for G6PDdef and 11.3% had abnormal results. Binomial testing comparing 11.3% (95% confidence interval (CI) 8.5 to 14.6) incidence of G6PDdef in NICU and reported incidence in NN (11%) demonstrated no difference. 12.2% of Black/African American males were not screened. CONCLUSION: FST is appropriate for screening all at-risk newborns. A number of at-risk premature males were not screened.
OBJECTIVE: Targeted screening for glucose-6-phosphate dehydrogenase deficiency (G6PDdef) using fluorescent spot test (FST) is done in our newborn nursery (NN) and now in our NICU. Premature infants have higher G6PD levels than term infants. FST may result in under diagnosis of G6PDdef in preterms. We sought to determine if FST is appropriate for diagnosis of G6PDdef at<35 weeks and assess screening in NICU. STUDY DESIGN: Retrospective chart review of male, inborninfants<35 weeks in NICU from 2008 to 2011. Difference in G6PDdef incidence<5% between NN and NICU was acceptable for equivalence. RESULTS: Out of 679 subjects, 442 were screened for G6PDdef and 11.3% had abnormal results. Binomial testing comparing 11.3% (95% confidence interval (CI) 8.5 to 14.6) incidence of G6PDdef in NICU and reported incidence in NN (11%) demonstrated no difference. 12.2% of Black/African American males were not screened. CONCLUSION: FST is appropriate for screening all at-risk newborns. A number of at-risk premature males were not screened.
Authors: O Mesner; C Hammerman; D Goldschmidt; B Rudensky; D Bader; M Kaplan Journal: Arch Dis Child Fetal Neonatal Ed Date: 2004-11 Impact factor: 5.747
Authors: Ella T Nkhoma; Charles Poole; Vani Vannappagari; Susan A Hall; Ernest Beutler Journal: Blood Cells Mol Dis Date: 2009-02-23 Impact factor: 3.039
Authors: O Ainoon; A Alawiyah; Y H Yu; S K Cheong; N H Hamidah; N Y Boo; M Zaleha Journal: Southeast Asian J Trop Med Public Health Date: 2003-06 Impact factor: 0.267
Authors: Vinod K Bhutani; Lois H Johnson; M Jeffrey Maisels; Thomas B Newman; Ciaran Phibbs; Ann R Stark; Marshalyn Yeargin-Allsopp Journal: J Perinatol Date: 2004-10 Impact factor: 2.521